These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7603184)

  • 21. [Hirudin--comeback of Hirudo medicinalis].
    Lassila R
    Duodecim; 1992; 108(6):535-7. PubMed ID: 1366111
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of new thrombin inhibitors in medical practice].
    Blaya C; Prati C; Boneti C; Bonamigo DR; Krumenauer RC; Rosito GA
    Arq Bras Cardiol; 1998 Aug; 71(2):163-7. PubMed ID: 9816691
    [No Abstract]   [Full Text] [Related]  

  • 23. Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis.
    Talbot M
    Semin Thromb Hemost; 1989 Jul; 15(3):293-301. PubMed ID: 2688102
    [No Abstract]   [Full Text] [Related]  

  • 24. Current developments in antithrombotic therapy: the role of antithrombin agents.
    Breddin HK
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 3():1-8. PubMed ID: 12811005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy.
    Kottke-Marchant K; Bahit MC; Granger CB; Zoldhelyi P; Ardissino D; Brooks L; Griffin JH; Potthoff RF; Van de Werf F; Califf RM; Topol EJ
    Eur Heart J; 2002 Aug; 23(15):1202-12. PubMed ID: 12127922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of recombinant hirudin.
    Nowak G
    Semin Thromb Hemost; 2002 Oct; 28(5):415-24. PubMed ID: 12420236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
    Kaiser B; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hirudin in heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Semin Thromb Hemost; 2002 Oct; 28(5):431-8. PubMed ID: 12420238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of recombinant hirudins in the management of thrombotic disorders.
    Fischer KG
    BioDrugs; 2004; 18(4):235-68. PubMed ID: 15244501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
    Elg M; Gustafsson D; Deinum J
    Thromb Haemost; 1997 Oct; 78(4):1286-92. PubMed ID: 9364999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.
    Doutremepuich C; Lalanne MC; Doutremepuich F; Walenga J; Fareed J; Breddin HK
    Haemostasis; 1991; 21 Suppl 1():99-106. PubMed ID: 1894201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in acute anticoagulation therapy: what improvements over traditional heparin are on the horizon?
    Carter CJ
    Postgrad Med; 1996 Jun; 99(6):129-36. PubMed ID: 8668626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development.
    Fareed J; Callas D; Hoppensteadt DA; Walenga JM; Bick RL
    Med Clin North Am; 1998 May; 82(3):569-86. PubMed ID: 9646780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of recombinant hirudin (LU 52369) on reocclusion rates after thrombolysis in rabbits.
    Rübsamen K; Eschenfelder V
    Haemostasis; 1991; 21 Suppl 1():93-8. PubMed ID: 1894200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the antithrombotic effects of heparin, hirudin and clopidogrel according to the nature of the thrombogenic surface in an arterioarterial shunt in rats.
    Léger P; Magues JP; Freund M; Cazenave JP; Boneu B
    Thromb Haemost; 1999 Sep; 82(3):1203-4. PubMed ID: 10494794
    [No Abstract]   [Full Text] [Related]  

  • 39. Neutralization of recombinant hirudin: some practical considerations.
    Fareed J; Walenga JM; Hoppensteadt D; Iyer L; Pifarre R
    Semin Thromb Hemost; 1991 Apr; 17(2):137-44. PubMed ID: 1771411
    [No Abstract]   [Full Text] [Related]  

  • 40. [Progress in the controlled release systems of hirudin].
    Li T; Wan C; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Dec; 15(4):419-23. PubMed ID: 12552793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.